Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR-T in Transplant-ineligible Newly Diagnosed Multiple Myeloma
NCT07070960Not yet recruiting
- Sponsor
- Xuzhou Medical University
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
01
Overview
Open-label, single-arm trial of anti-BCMA CAR-T in multiple myeloma (MM), sponsored by Xuzhou Medical University. Primary endpoints: Progression-Free Survival at 36 months and Overall Survival at 36 months. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
anti-BCMA CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07070960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070960.